Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma.

Huie M, Oettel K, Van Ummersen L, Kim KM, Zhang Y, Staab MJ, Horvath D, Marnocha R, Douglas J, Drezen A, Alberti D, Wilding G.

Invest New Drugs. 2006 May;24(3):255-60.

PMID:
16205854
2.

Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.

Vaishampayan U, Flaherty L, Du W, Hussain M.

Cancer. 2001 Aug 1;92(3):519-23.

PMID:
11505395
3.

Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.

Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM.

Urology. 2004 Jun;63(6):1061-5.

PMID:
15183950
4.
6.

A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.

Joffe JK, Banks RE, Forbes MA, Hallam S, Jenkins A, Patel PM, Hall GD, Velikova G, Adams J, Crossley A, Johnson PW, Whicher JT, Selby PJ.

Br J Urol. 1996 May;77(5):638-49.

PMID:
8689103
7.

Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.

Gez E, Rubinov R, Gaitini D, Meretyk S, Best LA, Native O, Stein A, Erlich N, Beny A, Zidan J, Haim N, Kuten A.

Cancer. 2002 Oct 15;95(8):1644-9.

8.

A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.

Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL.

Clin Cancer Res. 2000 Dec;6(12):4697-704.

9.

Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial.

Boccardo F, Rubagotti A, Canobbio L, Galligioni E, Sorio R, Lucenti A, Cognetti F, Ruggeri E, Landonio G, Baiocchi C, Besana C, Citterio G, De Rosa M, Calabresi F.

Tumori. 1998 Sep-Oct;84(5):534-9.

PMID:
9862512
11.

Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.

Pacheco AV, Rasila K, Lee SJ, Rabinowitz I, Elias L, Lee FC, Verschraegen CF.

Urol Oncol. 2008 Nov-Dec;26(6):610-5. doi: 10.1016/j.urolonc.2007.09.001. Epub 2008 Mar 4.

PMID:
18367103
12.
14.

Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP.

J Clin Oncol. 2007 Sep 1;25(25):3958-64.

PMID:
17761980
15.

A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.

Elias L, Blumenstein BA, Kish J, Flanigan RC, Wade JL, Lowe BA, Goodwin JW, Crawford ED.

Cancer. 1996 Sep 1;78(5):1085-8.

16.

Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.

Dutcher JP, Fisher RI, Weiss G, Aronson F, Margolin K, Louie A, Mier J, Caliendo G, Sosman JA, Eckardt JR, Ernest ML, Doroshow J, Atkins M.

Cancer J Sci Am. 1997 May-Jun;3(3):157-62.

PMID:
9161781
17.

A phase II study of interferon alpha and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma.

Piga A, Giordani P, Quattrone A, Giulioni M, De Signoribus G, Antognoli S, Cellerino R.

Cancer Immunol Immunother. 1997 Aug;44(6):348-51.

PMID:
9298938
18.

Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.

Culine S, Iborra F, Mottet N, Avancès C, de Graeve B, Volpé P, Vignoud J, Bringer JP, Marroncle M, Le Pellec L, Ayuso D, Jansen E, Faix A, Rebillard X.

Am J Clin Oncol. 2006 Apr;29(2):148-52.

PMID:
16601433
19.

Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial. The Japanese Study Group Against Renal Cancer.

Igarashi T, Marumo K, Onishi T, Kobayashi M, Aiba K, Tsushima T, Ozono S, Tomita Y, Terachi T, Satomi Y, Kawamura J.

Urology. 1999 Jan;53(1):53-9.

PMID:
9886588
20.

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.

Jayson GC, Middleton M, Lee SM, Ashcroft L, Thatcher N.

Br J Cancer. 1998 Aug;78(3):366-9.

Supplemental Content

Support Center